TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. - Wikidata - awgldk - TriplyDB

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

http://www.wikidata.org/entity/Q34557885

about

CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas Onto better TRAILs for cancer treatment Principles of antibody-mediated TNF receptor activation Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death.Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins.IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5.Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Therapeutic targeting of CD70 and CD27.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy.Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1.Structural principles of tumor necrosis factor superfamily signaling.Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors.IgG-single-chain TRAIL fusion proteins for tumour therapy.

P2860

Q26749139-3CD592C5-01E1-4D96-9BA4-37583586EA31 Q26768160-E19A8C1B-70D7-459E-8874-ACDEDC7B693E Q26796270-02A023BA-DBB2-4C95-A9B3-E8455CD5C1F7 Q27853200-274FE545-02B9-446E-A3FB-E7FA3BD4E56E Q33625907-A799B907-CB28-4E83-8470-D4F64CE62620 Q33632016-72429718-FDA9-451F-8126-E75294E98096 Q36103378-38F269E7-EFB6-4ACF-B334-0DBCAEDEAE06 Q37012681-81E9CDA6-76AF-46ED-A987-B6D43D6D5796 Q37024543-678CB4FB-7DC5-4AA3-9AC0-70332E71FE08 Q37114025-A873141C-E105-4BE3-80AF-905A8794F9B3 Q38749841-4D705B67-0FC5-43B4-8A4A-EFB5608DEC36 Q38770814-C4477060-F9AF-4732-9D7F-C6364190D9EC Q38885494-ECC04E55-BA0A-432B-B0EB-9662DBAEB1F9 Q38888391-480C3967-3AC0-4B65-BE21-8B9D385DD8E2 Q38945539-0BD83E8A-D666-4F28-9164-5CE491CD0130 Q41242816-C75D52A1-BDD8-40B1-8293-63DE4F8075F5 Q48319204-BBD9064D-3F6F-454E-A82B-782896A96BDD Q51760860-18C5EFC9-0EB2-4BDA-95BC-C09A41BAF0F9 Q52579567-573CD459-3729-4E48-BFCA-33EA38E77705 Q52715823-8B4898BE-B73D-41C6-87A7-324BCA543596 Q54998541-4EDD92A2-7582-4330-83B3-38085A5E17D4

P2860

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

http://www.wikidata.org/entity/Q34557885

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

@ast

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

@en

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

@nl

type

label

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

@ast

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

@en

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

@nl

prefLabel

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

@ast

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

@en

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

@nl

P1433

Q34557885-DB3C21DF-0188-493A-9605-F2470E143052

P1476

Q34557885-54D32ED5-79F2-48C5-9E15-5516D3B379DA

P2093

Q34557885-18AC1530-6FF2-4F61-B0AE-3031D68DE11B

Q34557885-35C4CD65-95CB-4AA3-8F46-CD713CEA8F87

Q34557885-51D1C90E-D67E-4C14-A3C0-70A5B5B94833

Q34557885-537320CD-1359-421A-961B-33A06112BC1A

Q34557885-55161C85-EC11-4CB6-B37E-14A82FB5EEF9

Q34557885-6086A046-D914-4C06-B9B3-A2DBD662AA61

Q34557885-8DA9ABF8-9952-4675-8CD6-F0474D9858C3

Q34557885-B3B09EFF-1361-42D1-81B1-A670E89AF7CE

Q34557885-D4D2DF60-C7E8-4E7D-A300-48D376B0CC7E

Q34557885-EE959A6B-4F54-4C1B-9E6C-906C5DFFC154

P2860

Q34557885-0192E966-D311-4F12-9756-C5049875BCF9

Q34557885-1364013B-2DCB-486D-A341-7EC0682B73B1

Q34557885-1CE79406-29F9-40B5-9936-A60AC16B328A

Q34557885-2273C94A-63AD-4BF4-B1D7-1F1F0F793DE5

Q34557885-2C61F347-5E0F-4D94-89C5-625AB2460C5D

Q34557885-3B4533C0-51CB-45AE-A07B-740565BAFCDE

Q34557885-3F2FA2CE-630B-4A67-B8D3-8AFB51036E01

Q34557885-42357052-A726-4176-BC0F-613C8E7DEF68

Q34557885-4EAAFFB0-EDD9-435A-98BE-C1E3FAB9EC06

Q34557885-5AFC6CA4-F3F7-45FD-9308-16F87EE4E0E3

P2888

Q34557885-834AF6EF-4B0F-4BA9-9C6D-96F5FD4178A9

P304

Q34557885-48159FEE-C623-4775-B9CA-AA3981C5B0AC

P31

Q34557885-6E144021-CE43-4434-B03F-DF8569CDE855

P356

Q34557885-250EBBEB-4367-4E57-B7EB-099807E09AA8

P407

Q34557885-522F33FA-8CCC-4670-97DF-9E11332C663A

P433

Q34557885-2E84DD28-3584-4F99-84E6-CF4A354E5AEF

P478

Q34557885-27342318-68FC-47B9-80E9-0EBB0D626768

P577

Q34557885-091557EB-11E3-4BC4-808A-8B6C87FE879F

P5875

Q34557885-6A6710B5-73AD-4679-B4E0-2D0058A3FA74

P6179

Q34557885-C22309B7-69FF-44B0-A3BE-065B55524B89

P698

Q34557885-FB3313C0-38FA-47AE-BEB2-B0E6C60D24ED

P921

Q34557885-A7008D82-EC6A-4908-BD54-329A27667D37

P932

Q34557885-32E61B1A-1797-4EBB-AE4B-495C346AD3A9

P356

P1433

P1476

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.

@en

P2093

Antonella Montinaro

http://www.w3.org/2001/XMLSchema#string

Henning Walczak

http://www.w3.org/2001/XMLSchema#string

Jonathan Graves

http://www.w3.org/2001/XMLSchema#string

Julia Zinngrebe

http://www.w3.org/2001/XMLSchema#string

Katharina Prieske

http://www.w3.org/2001/XMLSchema#string

Mark H Tuthill

http://www.w3.org/2001/XMLSchema#string

Peter Draber

http://www.w3.org/2001/XMLSchema#string

Silvia von Karstedt

http://www.w3.org/2001/XMLSchema#string

Stefan Prieske

http://www.w3.org/2001/XMLSchema#string

Tom Newsom-Davis

http://www.w3.org/2001/XMLSchema#string

P2860

A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Safety and antitumor activity of recombinant soluble Apo2 ligand.

The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells.

Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode

The peritoneal tumour microenvironment of high-grade serous ovarian cancer.

TRAIL signalling: decisions between life and death.

P2888

P304

2138-2144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2014.156

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262942114

http://www.w3.org/2001/XMLSchema#string

P6179

1025994906

http://www.w3.org/2001/XMLSchema#string

P698

24909167

http://www.w3.org/2001/XMLSchema#string

P921

P932

4240732

http://www.w3.org/2001/XMLSchema#string